

ॐ Omkar Pharmachem Ltd.

Date: 14/02/2018

To,
B S E Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001

Sub: - Unaudited Financial Result under Regulation 33 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015, for the Quarter and Nine Months ended 31st December, 2017

Company Scrip Code: 532167

Dear Sir,


Pursuant to the provisions of Regulation 33 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015, please find enclosed herewith, copy of the Unaudited Financial Results along with Limited Review Report of the Company, for the Quarter and Nine Months ended 31st December, 2017, for your kind perusal and reference.

The aforesaid result has been approved by the Board of Directors at their meeting held on 14th February, 2018.

This is for your information and record.

Thanking You,

Yours faithfully,
For **Omkar Pharmachem Limited**


(Anurag Sharma)
Managing Director
DIN-02289261
Add: A-727, Sarita Vihar, New Delhi-110076

Encl: a/a

ॐ Omkar Pharmachem Ltd.

Statement of Standalone Unaudited Financial Results for the Quarter & Nine Months ended on 31st December 2017

(Rs. in lacs except per share data)

Sr.	Particulars	Quarter Ended on			Nine Months Ended on	
		31-12-2017 (unaudited)	30-09-2017 (unaudited)	31-12-2016 (unaudited)	31-12-2017 (unaudited)	31-12-2016 (unaudited)
Part-I						
1	Income from operations					
	a) Net Sales/ Income from Operations	0.00	0.00	0.00	0.00	0.00
	b) Other Operating Income	0.00	0.00	0.00	0.00	0.00
	Net Total income from Operations	0.00	0.00	0.00	0.00	0.00
2	Expenses					
	a) Cost of material consumed	0.00	0.00	0.00	0.00	0.00
	b) Purchase of Stock-in-trade	0.00	0.00	0.00	0.00	0.00
	c) Changes in Inventories of Finished Goods, WIP and Stock-	0.00	0.00	0.00	0.00	0.00
	d) Employee benefits expenses	3.68	3.44	3.99	10.55	10.17
	f) Depreciation and Amortization Expenses	0.06	0.04	0.06	0.15	0.19
	g) Other Expenses	1.12	1.57	0.96	8.06	4.91
	Total Expenses	4.86	5.05	5.01	18.76	15.27
3	Profit(Loss) from operations before Other income, Finance cost, Exceptional Items & Taxes (1-2)	(4.86)	(5.05)	(5.01)	(18.76)	(15.27)
4	Other Income	0.00	0.00	0.12	0.00	0.55
5	Profit(Loss) before Finance cost, Exceptional Items & Taxes (3+4)	(4.86)	(5.05)	(4.89)	(18.76)	(14.72)
6	Finance Costs	0.00	0.01	0.00	0.05	0.00
7	Profit(Loss) from Ordinary Activities before Taxes and before exceptional items (5-6)	(4.86)	(5.06)	(4.89)	(18.81)	(14.72)
8	Exceptional items: Profit on sale of fixed assets	0.00	0.00	0.00	0.00	48.19
9	Profit(Loss) from Ordinary Activities before Tax(7-8)	(4.86)	(5.06)	(4.89)	(18.81)	33.47
10	Tax Expense	0.30	0.00	0.00	0.30	5.17
11	Profit(Loss) for the period (7+8)	(5.16)	(5.06)	(4.89)	(19.11)	28.30
12	Other Comprehensive Income (Expense)	0.00	0.00	0.00	0.00	0.00
13	Total Comprehensive Income for the period (9+10)	(5.16)	(5.06)	(4.89)	(19.11)	28.30
14	Paid up Equity Share Capital (Face Value Rs. 10/-each)	1008.37	1008.37	1008.37	1008.37	1008.37
14	Reserves excluding Revaluation Reserved as on 31st March	(70.65)	(70.65)	(92.71)	(70.65)	(92.71)
15	Earning Per Share(before & after extraordinary items)(of Rs. 10 each)(not annualised). Basic and diluted Rs.	(0.0512)	(0.0502)	(0.0485)	(0.1895)	0.2807

Notes: 1. The financial result for the Quarter & Nine Months ended on 31-12-2017 has been prepared in accordance the IND-AS specified under section 133 of the companies Act and rules made thereunder.

2. The above results have been reviewed by the audit committee & approved by the Board of Directors at there respective meetings held on 14th February 2018. The statutory Auditors of the Company has carried out Limited Review of the aforesaid results.

3. Corrospending previous period figures are regrouped/rearranged wherever necessary, to make them comparable.

4. The IND-AS regarding segment reporting is not applicable to the company as there is no segment.

5. Reserves includes reserves and surplus.

6. There is no change in Profit/Loss of the company due to the transition from Indian GAAP to IND-AS. Hence reconciliation statement is not required.

Date : 14-02-2018

Place: Ahmedabad

By order of the Board


(Anurag Sharma)

Managing Director

DIN-02289261

Add- A-727, Sarita Vihar,

New Delhi-110076



Limited review report to The Board of Directors of Omkar Pharmachem Limited for quarter and nine months ended on 31st December, 2017

We have reviewed the accompanying statement of unaudited financial results of Omkar Pharmachem Limited for the quarter and nine months ended on 31st December, 2017. This statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "**Review of Interim Financial Information Performed by the Independent Auditor of the Entity**" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and; thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Ahmedabad
Date : 14/02/2018



For Rajesh J. Shah & Associates
Chartered Accountants
FRN 108407W


(Rajesh J. Shah)
Partner